The Drug Utility System (PBS) is highly respected internationally and provides today`s government with a solid basis for making decisions about drug subsidies. As demand increases, the pressure on existing systems, which requires a certain degree of change, is increasing. As part of Clause 10 of the agreement, the implementation of drug implementation processes, a number of objectives have been set to improve the efficiency, transparency and timeliness of the pbs list processes, including: two advisory forums were held in September 2018 with Industry, Consumers and Clinicians. In October and November 2018, Medicines Australia organized four additional consulting forums directly with the industry on behalf of AMWG-SPS. All the forums were held in either Sydney or Melbourne. The Generic Medicines Industry Association (GMiA) has signed a strategic agreement with the Australian government to support the supply of affordable generic and biosimilar drugs in Australia and provide a five-year security period for the industry that supplies them. This agreement has been extended for a further two years. The extension document can be viewed at the bottom of this page. “The GMiA and the government have a common interest in continued and reliable access to affordable generic drugs and biosimilars, a strong PBS capable of meeting the current and future needs of Australians, and a sustainable generic drug sector,” he said. Access to medicines for Australian health consumers is supported by the national pharmaceutical policy introduced in 1999. National pharmaceutical policy has four major objectives: on April 27, 2017, the government signed a five-year strategic agreement with Medicines Australia, in which both sides recognize the commitment to a viable pharmaceutical sector in Australia and a sustainable STRATEGY. The 2016-2017 federal budget confirms that the drug efficacy program is stable and will continue to ensure that Australian patients have access to safe and effective medicines after years of significant drug reforms in this sector. “Every time a patient or health care professional uses a generic drug or biosimilar, it saves money that can be used for newer drugs.
GMiA members have and will continue to provide billions of dollars in PBS savings,” said Mark Crotty, President of GMiA (2015). A new publication, which explains the drug subsidy system for Australian patients, was published today at Parliament House in Canberra at the Medicines Partnership of Australia. The recent study on the impact of a significant increase in co-payment concluded that the increase in patient contributions had a particular impact on the ability of dealers to afford drugs. This is an impact that should be of concern to policy makers. The agreement recognizes the essential role of generic drugs and biosimilars in providing affordable health care through the Pharmaceutical Benefits Scheme (PBS). It also recognizes the significant savings that continue to be realized through generic drugs and biosimilars, first through competition and then through price disclosure. “Today, many of us are personally affected by our PBS-subsidized health and productivity drugs, and we all have parents, friends and voters who rely on the program to get the drugs they need.